US Bancorp DE boosted its stake in shares of Gilead Sciences (NASDAQ:GILD) by 4.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,171,072 shares of the biopharmaceutical company’s stock after purchasing an additional 52,618 shares during the period. US Bancorp DE owned about 0.09% of Gilead Sciences worth $88,287,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Capital International Investors lifted its position in shares of Gilead Sciences by 86.6% in the third quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock valued at $908,803,000 after acquiring an additional 5,205,983 shares in the last quarter. Sanders Capital LLC lifted its position in shares of Gilead Sciences by 102.9% in the fourth quarter. Sanders Capital LLC now owns 9,910,493 shares of the biopharmaceutical company’s stock valued at $757,119,000 after acquiring an additional 5,026,015 shares in the last quarter. Skandinaviska Enskilda Banken AB publ lifted its position in shares of Gilead Sciences by 230.0% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 4,927,585 shares of the biopharmaceutical company’s stock valued at $399,233,000 after acquiring an additional 3,434,450 shares in the last quarter. CI Global Investments Inc. lifted its position in shares of Gilead Sciences by 5,461.1% in the fourth quarter. CI Global Investments Inc. now owns 3,317,627 shares of the biopharmaceutical company’s stock valued at $237,675,000 after acquiring an additional 3,257,969 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. lifted its position in shares of Gilead Sciences by 53.3% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 9,054,685 shares of the biopharmaceutical company’s stock valued at $648,679,000 after acquiring an additional 3,148,128 shares in the last quarter. Institutional investors own 77.72% of the company’s stock.
Several equities analysts have recently commented on GILD shares. Leerink Swann restated a “market perform” rating and issued a $80.00 price objective (down from $83.00) on shares of Gilead Sciences in a research report on Thursday, February 22nd. Zacks Investment Research raised Gilead Sciences from a “sell” rating to a “buy” rating and set a $85.00 target price on the stock in a report on Thursday, April 19th. ValuEngine raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Barclays reduced their target price on Gilead Sciences from $95.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, May 2nd. Finally, Citigroup raised Gilead Sciences from a “neutral” rating to a “buy” rating and reduced their target price for the stock from $88.80 to $76.00 in a report on Tuesday, January 30th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and a consensus price target of $88.14.
In other news, CFO Robin L. Washington sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total transaction of $401,550.00. Following the transaction, the chief financial officer now owns 23,749 shares of the company’s stock, valued at $1,907,282.19. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman John C. Martin sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $78.65, for a total value of $3,932,500.00. Following the transaction, the chairman now directly owns 3,067,762 shares in the company, valued at approximately $241,279,481.30. The disclosure for this sale can be found here. Insiders have sold 226,667 shares of company stock worth $17,060,854 over the last three months. 1.16% of the stock is currently owned by insiders.
Shares of Gilead Sciences opened at $67.63 on Tuesday, according to Marketbeat. The company has a current ratio of 2.84, a quick ratio of 2.75 and a debt-to-equity ratio of 1.32. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $89.54. The company has a market cap of $88.44 billion, a price-to-earnings ratio of 7.90, a P/E/G ratio of -5.91 and a beta of 1.19.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.67 by ($0.19). Gilead Sciences had a return on equity of 45.49% and a net margin of 14.03%. The company had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $5.40 billion. During the same period in the previous year, the firm earned $2.23 earnings per share. The company’s revenue was down 21.8% compared to the same quarter last year. analysts predict that Gilead Sciences will post 5.75 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 28th. Shareholders of record on Friday, June 15th will be paid a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, June 14th. This represents a $2.28 annualized dividend and a yield of 3.37%. Gilead Sciences’s payout ratio is currently 26.64%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.